27 September 2006: Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, gives notice that, on 26 September 2006, following the exercise of warrants to subscribe shares in Enact Pharma Ltd (a wholly owned subsidiary of Protherics), Protherics exercised its rights to repurchase the Enact Pharma shares by issuing additional 6% unsecured convertible loan notes 2010 (the "Loan Notes") with a total nominal value of GBP17,050 which form a single series with the existing 6% unsecured convertible loan notes 2010.
